ReviewThe European respiratory journal2019
Haemodynamic definitions and updated clinical classification of pulmonary hypertension.
Review in The European respiratory journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 8 registered trials, which are not on this map. Cited by 1,893 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Echocardiographic Indices and Blood Biomarkers in Group 1 Pulmonary Hypertension
Characteristics of Pulmonary Vascular Changes in Patients With Kidney Transplantation
Pulmonary Hypertension in Patients Attending Sohag University Hospital: A Focus on The Etiology
Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH
Impact of Pulmonary Endarterectomy on Sleep-Related Breathing Disorders and Mortality in Chronic Thromboembolic Pulmonary Hypertension - The IPES Trial: A Prospective, Observational, Cohort Study
Investigation of the Effects of the Otago Exercise Program in Adults With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease
Efficacy and Safety of High-Flow Nasal Cannula Versus Noninvasive Ventilation for Pulmonary Arterial Hypertension-Associated Acute Respiratory Failure: A Retrospective Cohort Study Stratified by Right Ventricular Dysfunction Severity
Pulmonary Hypertension (PH) Biorepository for Translational Research
Who cites it
1,893 citing papers in PubMed, 8 syntheses or guidelines pooled it, 3,743 citations in OpenAlex.
- Indirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review.Reviews in cardiovascular medicine · 2026Pooled it
- Pooled it
- Evaluating the Impact of Inspiratory Muscle Training on Respiratory Function and Exercise Capacity in Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Advances in respiratory medicine · 2026Pooled it
- International Liver Transplantation Society practice guideline update on portopulmonary hypertension.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026Guideline
- International Liver Transplantation Society practice guideline update on portopulmonary hypertension.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026Guideline
- Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Methodological Quality of Pulmonary Arterial Hypertension Treatment Evidence-Based Guidelines: A Systematic Review Using the AGREE II and AGREE REX Tools.Cardiovascular drugs and therapy · 2025Pooled it
- Phosphodiesterase type 5 inhibitor plus endothelin receptor antagonist compared to either alone for group 1 pulmonary arterial hypertension.The Cochrane database of systematic reviews · 2025Pooled it
- Pharmacokinetics, Safety Profile, and Tolerability of MN-08 Tablets after Single and Multiple Ascending Doses in Healthy Chinese Volunteers.Clinical drug investigation · 2026Trial
- Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension.Thorax · 2025Trial
- Correlating Pulmonary Hemodynamics With HPMagnetic resonance in medicine · 2026Article
- Pulmonary Veno-Occlusive Disease Presenting as Congenital Heart Disease-Associated Pulmonary Hypertension.JACC. Case reports · 2026Article
- From snapshot to trajectory: A multimodality right-heart monitoring framework across the heart failure spectrum.American heart journal plus : cardiology research and practice · 2026Review
- Fatty Acid and Oxylipin Metabolism Differentiate Isolated Postcapillary From Combined Pre- and Postcapillary Pulmonary Hypertension.Circulation. Heart failure · 2026Article
- Role of PET imaging in evaluating right ventricular function and prognosis in pulmonary hypertension.Clinics (Sao Paulo, Brazil) · 2026Review
- Delays in the diagnosis and management of pulmonary arterial hypertension: a simulated patient cases study across four European countries.ERJ open research · 2026Article
- An Ancient Founder GDF2 Variant Potentially Causes Semi-Dominant Non-Syndromic Pulmonary Arterial Hypertension.Clinical genetics · 2026Article
- The clinical relevance of chest computed tomography imaging in pulmonary hypertension associated with lung diseases.Current opinion in pulmonary medicine · 2026Review
- Registry-based estimation of cardiac event-free survival in congenital heart disease complicated by pulmonary hypertension: A nationwide registry study from Japan.International journal of cardiology. Congenital heart disease · 2026Article
- Development of a Preoperative Transthoracic Echocardiography-Based Nomogram for Predicting 1-Year Cardiovascular Events in End-Stage Renal Disease Kidney Transplant Recipients.Echocardiography (Mount Kisco, N.Y.) · 2026Article
1,833 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP >20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management.Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup "pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers", due to the specific prognostic and management of these patients, and a subgroup "PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement", due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.